SCHEMBL24166133

SCHEMBL24166133

COCCn1c(-c2ccccn2)nc2ccc(N)cc2c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CDK9 P50750 1/20 0.42
DYRK1A Q13627 1/20 0.42
DYRK2 Q92630 1/20 0.42
CYP1A2 P05177 4/20 0.41
CYP3A4 P08684 3/20 0.41
RXFP1 Q9HBX9 2/20 0.41
USP2 O75604 1/20 0.41
CYP2C19 P33261 1/20 0.41
PDE4D Q08499 1/20 0.41
POLB P06746 2/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30656844 1.00 ALDH1A1 (0.43) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL30656870 0.86 ALDH1A1 (0.43) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL24166134 0.86 ALDH1A1 (0.43) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL30656802 0.84 CYP19A1 (0.52) SMN1; SMN2L3MBTL1POLB
SCHEMBL26758129 0.84 CYP19A1 (0.52) SMN1; SMN2L3MBTL1POLB
SCHEMBL24166099 0.81 ABCC1 (0.48) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL30656824 0.81 ABCC1 (0.48) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL24166490 0.81 ALDH1A1 (0.60) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL30656860 0.81 ALDH1A1 (0.60) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL24166087 0.80 MAPT (0.52) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
WO-2022003712-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC ALDH1A1 295/4885HPGD 2422/4885KDM4E 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.